Lamotrigine

Generic Name: Lamotrigine

Brand Names: Lamictal

Drug Type: Small Molecule

Chemical Formula: C_₉H_₇Cl_₂N_₅

CAS Number: 84057-84-1

Unique Ingredient Identifier: U3H27498KS

Background: Lamotrigine is an antiepileptic drug belonging in the phenyltriazine class. It is used in the treatment of both epilepsy and as a mood stabilizer in bipolar disorder. Lamotrigine is the first medication since lithium granted Food and Drug Administration (FDA) approval for the maintenance treatment of bipolar type I. It is approved for use in more than 30 cou...

Indication: Lamotrigine is indicated as adjunctive therapy for the following seizure types in patients ≥2 years of age: partial seizures, primary generalized tonic-clonic seizures, and generalized seizures due to Lennox-Gastaut syndrome.
...

Associated Conditions: Bipolar 1 Disorder, Generalized Tonic-Clonic Seizures, Partial-Onset Seizures, Seizures, Generalized

Associated Therapies: Conversion to monotherapy

Clinical Trials

Pharmacokinetic Study on Raltegravir and Lamotrigine

Phase 1

Completed

Conditions: HIV Infection

Interventions: Drug: lamotrigine
Drug: Raltegravir

First Posted Date: 2008-02-19

Last Posted Date: 2020-10-19

Lead Sponsor: Radboud University Medical Center

Target Recruit Count: 24

Registration Number: NCT00618241

Locations: 🇳🇱
Radboud University Medical Center, Nijmegen, Gelderland, Netherlands

Premenstrual Dysphoric Disorder and Antiepileptic Drugs

Completed

Conditions: Epilepsy

Interventions: Drug: Lamotrigine
Other: No Intervention
Drug: Levetiracetam
Drug: Carbamazepine

First Posted Date: 2008-02-11

Last Posted Date: 2018-10-26

Lead Sponsor: Beth Israel Deaconess Medical Center

Target Recruit Count: 80

Registration Number: NCT00612235

Locations: 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Newton-Wellesley Hospital, Newton, Massachusetts, United States

An Open-Label Trial Measuring Satisfaction And Convenience Of Two Formulations Of Lamotrigine In Subjects With A Mood Disorder

Phase 3

Completed

Conditions: Mood Disorders

Interventions: Drug: Lamotrigine

First Posted Date: 2007-12-24

Last Posted Date: 2016-12-16

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 97

Registration Number: NCT00579982

Locations: 🇺🇸
GSK Investigational Site, Charleston, West Virginia, United States

The Use of Anticonvulsants for Treatment of Patients With Alcohol Dependence and Post Traumatic Stress Disorder

Phase 3

Withdrawn

Conditions: Alcohol Dependence
Post Traumatic Stress Disorder

Interventions: Other: Placebo
Drug: Topiramate
Drug: lamotrigine

First Posted Date: 2007-12-11

Last Posted Date: 2020-11-16

Lead Sponsor: Yale University

Registration Number: NCT00571246

Locations: 🇺🇸
VA Connecticut Healthcare System, West Haven, Connecticut, United States

An Evaluation Of BW430C (Lamotrigine) Versus Placebo In The Prevention Of Mood Episodes In Bipolar I Disorder Patients

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Placebo
Drug: lamotrigine

First Posted Date: 2007-10-29

Last Posted Date: 2016-11-23

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 215

Registration Number: NCT00550407

Locations: 🇯🇵
GSK Investigational Site, Yamagata, Japan

Lamotrigine Extended-Release In Elderly Patients With Epilepsy

Phase 3

Completed

Conditions: Epilepsy

Interventions: Drug: Lamotrigine

First Posted Date: 2007-08-15

Last Posted Date: 2017-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 122

Registration Number: NCT00516139

Locations: 🇺🇸
GSK Investigational Site, Milwaukee, Wisconsin, United States

Olanzapine/Fluoxetine Combination Versus Comparator in the Treatment of Bipolar I Depression

Phase 4

Completed

Conditions: Bipolar Disorder

First Posted Date: 2007-06-13

Last Posted Date: 2007-06-13

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 403

Registration Number: NCT00485771

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Lafayette, Indiana, United States

Lamotrigine Alone Compared to Lamotrigine Plus Antidepressant for the Treatment of Bipolar II Depression

Phase 2

Completed

Conditions: Bipolar II Disorder, Most Recent Episode Major Depressive

Interventions: Drug: Lamotrigine

First Posted Date: 2007-05-17

Last Posted Date: 2015-06-04

Lead Sponsor: University of British Columbia

Target Recruit Count: 15

Registration Number: NCT00475137

Locations: 🇨🇦
University of British Columbia Mood Disorders Centre, Vancouver, British Columbia, Canada

Lamictal Bipolar Observational Study

Completed

Conditions: Bipolar Disorder

Interventions: Drug: lamotrigine

First Posted Date: 2007-04-13

Last Posted Date: 2012-03-19

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 238

Registration Number: NCT00460226

Study on the Treatment of Elderly Patients With Older and Newer Antiepileptic Drugs

Phase 4

Completed

Conditions: Focal Epilepsy

Interventions: Drug: Levetiracetam
Drug: Carbamazepine
Drug: Lamotrigine

First Posted Date: 2007-02-22

Last Posted Date: 2013-02-28

Lead Sponsor: Johannes Gutenberg University Mainz

Target Recruit Count: 361

Registration Number: NCT00438451

Locations: 🇩🇪
Department of Neurology, University of Mainz Medical Centre, Mainz, Germany

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy